Find more information about Teva in your location, or contact a local representative on our local sites
North America
International Markets
North America
Toggle North America
International Markets
Toggle International Markets
Europe
Toggle Europe
Safety of New Formulation of Glatiramer Acetate (Song)
- Study Title
- Safety of New Formulation of Glatiramer Acetate
- Teva Identifier
- PM033
- ClinicalTrials.gov Identifier
- NCT00947752
- Study Status
- Completed
- Trial Condition(s)
- Relapsing Remitting Multiple Sclerosis
- Interventions
- Drug: Glatiramer Acetate | Drug: Experimental Glatiramer Acetate
Study Description
Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age Range
- 18 Years and older
- Trial Duration
- 07/01/2009 - 11/01/2009
- Phase
- Phase 3
